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Background: Recently, the importance of cytogenetics has grown in the diagnosis, prognosis and
treatment of leukemias and myelodysplastic syndromes. 5-azacytidine is a drug that has well-known
cytogenetical effects and is approved in the treatment of myelodysplastic syndromes. To date, no
studies have been performed to evaluate the impact of 5-azacytidine on the chromosomes of patients
with hematological neoplasias. This study aimed to investigate the effects of 5-azacytidine on
chromosomes of patients with different hematological malignancies using G-band analyses to identify
possible cytogenetical alterations.
Methods: The peripheral blood of 18 patients with hematological malignancies and 18 controls was
collected in heparinized tubes. 5-azacytidine was added, at a final concentration of 10-5M, to cultures
7 hours prior to harvest.
Results: Uncoiled centromeric/pericentromeric heterochromatin of chromosomes-1, 9 and 16 occurred
more frequently in the patients than in controls. This higher frequency of uncoiled heterochromatin
was statistically significant (p-value = 0.004) for chromosome-9. Conversely, we observed that the
fragile site at 19q13 was more frequent in controls (p-value = 0.0468).
Conclusions: The results of this study suggest that satellite sequences, located in the heterochromatin
of chromosome-9, are hypomethylated in hematological malignancies. This hypomethylation may
contribute to the disease, activating transposable elements and/or promoting genomic instability,
enabling the loss of heterozygosity of important tumor suppressor genes. An investigation of the
19q13 region may help to understand whether or not the predominant occurrence of the fragile site at
19q13 in controls is due to hypermethylation of this region.
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Introduction
Leukemias and myelodysplastic syndromes (MDS) are both clonal hematopoietic
stem cell disorders, but while MDS is characterized by ineffective hematopoiesis,
peripheral cytopenias and cytological atypia in one or more myeloid cell lineages,
leukemias involve overproliferation of hematopoietic stem cells which when added to
their failure to differentiate leads to an accumulation of non-functional cells, known as
blasts, in the bone marrow and the peripheral blood.(1-4) About 30% of MDS cases
evolve to acute myeloid leukemia (AML), thus MDS is considered a pre-leukemia
disease.(5) Aberrant karyotypes are found in 30-50% of MDS, 40% of AML, 64-85% of
adult acute lymphoid leukemia (ALL), 60-69% of pediatric ALL and in 95% of chronic
myeloid leukemia (CML).(2-5)
 Pretreatment cytogenetic findings have repeatedly proved to be among the most
important independent prognostic factors for AML and ALL.(4) Chromosomal analyses
are important prognostic markers; this is one of the parameters evaluated by the
International Prognostic Scoring System (IPSS), the gold standard for risk assessment
of patients with de novo MDS.(1)
DNA methylation is an epigenetic process, meaning it has heritable information
other than the DNA sequence involved in gene expression.(6,7) This process is essential
for embryonic development, tissue differentiation, X chromosome inactivation in females
and imprinting.(7,8) Epigenetic alterations have gained increasing recognition as important
participants in tumor development and progression.(9) Abnormal DNA methylation patterns
have been recognized in cancer cells for over two decades.(10) It is well established that
although the genome as a whole is hypomethylated in cancer, CpG islands located in
promoter regions of certain genes are found hypermethylated.(9,11-16) In experimental
settings, demethylating agents are capable of reactivating tumor suppressor genes
silenced by promoter hypermethylation.(14) 5-azacytidine (5-AZC) is a cytidine analog, in
which a nitrogen atom replaces the carbon in the 5 position of the pyrimidine ring. As a
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result, when 5-AZC is incorporated into DNA, it cannot be
methylated.(17) Low doses of 5-AZC induce DNA
demethylation in malignant myeloid cells. The use of 5-AZC
in clinical trials yielded positive results and so this was the
first drug to be approved by the US Food and Drug
Administration (FDA) for the treatment of MDS.(18)
When added into human lymphocyte cultures, 5-AZC
is known to cause uncoiling of the centromeric/
pericentromeric heterochromatic regions (Figure 1A) of
chromosomes 1, 9, 15, 16 and Y, allowing associations between
these under-condensed regions (Figure 1B), which occurs
during the interphase.(19,20) Cytogenetically, this
demethylating agent also induces the formation of the fragile
sites at 1q42 and 19q13 (Figure 1C) and, after 2 cycles of
replication, it provokes differential under-condensation of
sister-chromatids. (21,22)
In spite of the central role played by cytogenetics in
the diagnosis, prognosis and treatment choice of leukemias
and MDS, and of 5-AZC being a drug of well reported
cytogenetical effects used to treat these diseases, no studies
have been performed to evaluate the impact of 5-AZC on
chromosomes of patients diagnosed with hematological
neoplasias.
This study aimed to investigate the effects of the
demethylating agent, 5-AZC, on chromosomes of patients
with different hematological malignancies. In addition, G-
band analyses were performed to detect possible
chromosomal rearrangements in the peripheral lymphocytes
of patients.
Figure 1 – Metaphases exhibiting: (A) uncoiled heterochromatic regions
of chromosomes 1, 9 and 16: (B) an association between uncoiled
heterochromatic of chromosomes 1, 9 and 16: (C) the 1q42 and
19q13 fragile sites: (D) Philadelphia (Ph) and derivative 9 (9t)
chromosome
Methods
Samples
Heparinized peripheral blood samples from 13 female
and 5 male patients with hematological malignancies were
obtained at diagnosis ofmalignancies in the Hematology
Department of FAMEMA (Faculdade de Medicina de Marília,
SP, Brazil). The peripheral blood of 18 individuals, without
history of neoplasias, matched for age (± 5 years) and gender
to the patients was also collected and used as a control group.
All subjects gave their informed consent to participate and
this study which was approved by the local Ethics Committee.
Blood culture and 5-azacytidine treatment
Blood cells were seeded in RPMI 1640 medium
supplemented with 10% fetal calf serum and incubated for 72
hours at 37oC in a 5% CO2 atmosphere. 5-AZC was added to
the culture 7 hours prior to harvest at a final concentration of
10-5 M. Harvesting was performed as described by the AGT
Cytogenetics Laboratory Manual.(23)
Slide preparation and staining techniques
Slides were prepared following conventional
techniques. Slides of 5-AZC-treated cultures were stained
with 5% Giemsa for 8 minutes. Non-treated cultures of the
patients were stained according to the G-band technique as
described by the AGT Cytogenetics Laboratory Manual.(23)
Cytogenetic analysis
One hundred Giemsa-stained 5-AZC-treated
metaphases were analyzed for each subject. The parameters
evaluated were: 1) the number of under-condensations of
the heterochromatin of chromosomes 1, 9 and 16, 2) the
occurrence of the fragile sites at 1q42 and 19q13 or other
chromosomal lesions and 3) the presence of associations
between uncoiled regions. Analyses were performed in a blind
manner. Ten G-band metaphases of each patient were analyzed
in order to investigate possible chromosomal alterations in
these individuals.
The Mann-Whitney test was used to analyze the
number of uncoiled heterochromatic regions of the human
chromosomes 1, 9 and 16 and the number of associations
between uncoiled regions and the Poisson test was used to
analyze the fragile sites at 1q42 and 19q13. A level of
significance was adopted for a p-value = 0.05 (Bioestat 5
software).
Results
Through G-band analyses, the only consistent
chromosomal abnormality found in patients was the
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Philadelphia chromosome in all 3 patients diagnosed with
CML.
Patients 4 and 9 had Down's syndrome and therefore
an extra chromosome 21 was observed in all metaphases of
these individuals.
Our results showed that the centromeric/
pericentromeric heterochromatin of chromosomes 1, 9 and 16
were more frequently uncoiled in the group of patients
compared to the control group and this higher frequency of
uncoiled heterochromatin was statistically significant (p-value
= 0.004) for chromosome 9 (Table 1).
Discussion
The cytogenetical effects of 5-AZC were first described
in 1976(19-22) and its use in the treatment of MDS was approved
by the US FDA in 2004.(24,25) Nevertheless, to date, studies
evaluating the effects of 5-AZC on chromosomes of patients
with hematological malignancies are unavailable in the
literature.
Recently, cytogenetic analyses have gained importance
in the diagnosis, prognosis and treatment choice for
hematological malignancies. In the present study, the effects
of exposure to 5-AZC were observed on the chromosomes of
patients newly diagnosed with hematological malignancies.
The low incidence of cytogenetical abnormalities in the
patients could be due to the fact that the samples were
collected from peripheral blood instead of bone marrow. This
finding suggests that the heterochromatic region of
chromosome 9 is hypomethylated in patients, because it is
more sensitive to the drug. The results are in accordance to
what is described in the literature regarding neoplasias and
hypomethylation.
Heterochromatin located in the centromeric/
pericentromeric region of chromosomes 1, 9 and 16 is mainly
constituted by repetitive sequences known as satellites. The
centromeric regions are rich in satellite a (Sat a), whereas the
pericentromeric regions of chromosomes 1 and 16 are mainly
constituted by satellite 2 (Sat 2) and of chromosome 9 by
satellite 3 (Sat 3). In normal tissue, those regions are found
heavily methylated.(26,27) It is possible that the higher
frequency of uncoiled centromeric/pericentromeric
heterochromatin of chromosome 9, observed in the patients,
reflects alterations in the patterns of Sat 3 methylation in
these individuals. On studying urothelial carcinoma,
Nakagawa et al.(28) observed loss of heterozygosity (LOH) of
chromosome 9 in more than half of the cases (52%) and, in
the cases where LOH of chromosome 9 was detected, rather
large regions of 9p and/or 9q were lost. DNA hypomethylation
of Sat 2 and Sat 3 was significantly correlated with LOH of
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chromosome 9 in this neoplasia. Thus, the study concluded
that DNA hypomethylation of pericentromeric satellite regions
may participate in the development and progression of
urothelial carcinomas by inducing loss of heterozygosity of
chromosome 9. It is possible that hypomethylation of satellite
sequences can contribute to the occurrence and progression
of hematological malignancies as well. Fragile sites at 1q42
and 19q13 were more common in the control group than in
patients, but the difference was only statistically significant
(p-value = 0.0468) for 19q13 (Table 2).
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One possible explanation for this finding is that the
19q13 region is hypermethylated in patients and, therefore,
is less sensitive to the action of 5-AZC. We can speculate
that, in the 19q13 region, there is a tumor suppressor gene
whose silencing through methylation favors the development
of the neoplasia. The LOH of the 19q13 region is commonly
found in neuroblastomas and gliomas, suggesting the
existence of an important tumor suppressor gene in this region
involved in the development of these cancers. One candidate
gene is the epithelial membrane protein 3 (EMP3).(29)
Nevertheless, studies associating hypermethylation of
either the EMP3 gene or the 19q13 band and hematological
malignancies were not found in the literature. The induction
of hypomethylation using 5-AZC provokes translocations
between satellite regions in the second cell generation,
probably resulting from the somatic associations observed
between regions in the first cell generation.(30) Associations
involving the uncoiled regions of chromosomes 1, 9 and 16
did not statistically differ between patients and the control
group. However, patients 3, 5, 7 and 17 presented respectively
16, 9, 14 and 10 associations whereas the highest number of
associations found in the control group was 6 (Table 3). The
high frequency of associations exhibited by these 4 patients
could be indicative that the satellite regions of these
individuals are more unstable.
As previously mentioned, in cancer, the genome as a
whole is hypomethylated and the loss of methyl groups
occurs mainly in the body of genes and in the repetitive
sequences, such as the sequences present in the
heterochromatic region of chromosomes 1, 9 and 16. Overall
hypomethylation has the potential to contribute to a
malignant phenotype through chromosomal instability,
reactivation of transposable elements, and loss of normal
gene imprinting patterns.(14,26) The results of this study
showed that the centromeric/pericentromeric heterochromatin
of chromosomes 1, 9 and 16 appeared more frequently
uncoiled in the group of patients compared to the control
group and this higher frequency of uncoiled heterochromatin
was statistically significant (p-value = 0.004) for chromosome
9 (Table 1). This finding suggests that the heterochromatic
region of chromosome 9 is hypomethylated in patients
because it is more sensitive to the drug. Results suggest that
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the satellite DNA of chromosome 9 is hypomethylated in
patients with different hematological malignancies. It is
possible that this hypomethylation contributes to the
pathogenesis of these neoplasias by activating parasite
sequences and/or promoting chromosomal instability. In
addition, the higher frequency of the fragile site at 19q13 in
the control group may indicate that that region is
hypermethylated in patients; nonetheless molecular studies
searching for candidate tumor suppressor genes involved
in the development and/or progression of hematological
malignancies located in the 19q13 band are necessary in
order to prove this finding. The increased occurrence of
associations between the uncoiled regions of chromosomes
1, 9 and 16 observed in 4 patients could be a sign that the
satellite DNA in these individuals is unstable.
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